Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SANTIAGO, Chile, June 10, 2013 (GLOBE NEWSWIRE) -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced the initiation of their Phase II clinical study investigating the use of TI-001, intranasal oxytocin, for the treatment of chronic migraine. The placebo-controlled, double-blind, randomized-withdrawal and enrollment enriched study, TRIG-05, officially began its enrollment period on May 31, 2013, and is expected to enroll 96 chronic migraine patients at trial sites located in Chile, with additional sites in Argentina expected to join in July. The first patient was enrolled in the study and treated on June 6, 2013.
Help employers find you! Check out all the jobs and post your resume.
